NCT05802407 The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
| NCT ID | NCT05802407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-02-01 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-02-01 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.
Eligibility Criteria
Inclusion Criteria: * patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection); * both sexes, age ≥18 years old; * ECOG performance status score ≤2; * the expected survival time was ≥3 months. Exclusion Criteria: * a known diagnosis of pancreatic cancer other than ductal adenocarcinoma; * treated with any systemic antitumor treatment before first-line chemotherapy onset; * died or lost to follow-up within one month after the initiation of adjuvant chemotherpay; * combined with other primary malignances.
Contact & Investigator
Chunmei Bai, MD
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT05802407 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05802407 currently recruiting?
Yes, NCT05802407 is actively recruiting participants. Contact the research team at tangh160706@163.com for enrollment information.
Where is the NCT05802407 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05802407 clinical trial?
NCT05802407 is sponsored by Peking Union Medical College Hospital. The principal investigator is Chunmei Bai, MD at Peking Union Medical College Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.